Login to Your Account

FDA Grants Priority Review to Vanda's Tasimelteon

By Catherine Shaffer
Staff Writer

Tuesday, July 30, 2013
Vanda Pharmaceuticals Inc., of Washington, was granted priority review status for tasimelteon, its candidate for non-24-hour disorder in people who are totally blind. Non-24 affects a majority of blind people, or 65,000 to 95,000 people in the U.S.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription